Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TROPION-Lung05 of datopotamab deruxtecan in previously treated actionable genomic alteration-positive advanced or metastatic non-small cell lung cancer
jRCT2041200097Phase 2Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Mar 2021
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of datopotamab deruxtecan in non-small cell lung cancer (NSCLC), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoint: Objective response rate. Started Mar 2021; status: completed.
02
Drugs
datopotamab deruxtecan
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2041200097.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041200097.